Maestro 9.4 as a Tool in the Structure Based Screening of Glycoalkaloids and Related Compounds, Targeting Aldose Reductase

M. J. Firdhouse, P. Lalitha
{"title":"Maestro 9.4 as a Tool in the Structure Based Screening of Glycoalkaloids and Related Compounds, Targeting Aldose Reductase","authors":"M. J. Firdhouse, P. Lalitha","doi":"10.3923/TB.2015.26.36","DOIUrl":null,"url":null,"abstract":"Diabetes mellitus is one of the alarming common diseases of this century. In India, according to the statistics of the International Diabetes Federation, 87 million of people are affected by Diabetes mellitus and this number is expected to cross 100 million by 2030. This has created a thrust for the development of new medicines. Recently, ban of pioglitazone, an oral anti-diabetic drug by Drugs Technical Advisory Board (DTAB) on account of its side effects, portrays the need for developing new drugs with less or no side effects. Cheminformatics tools assist in screening several millions of compounds and providing lead compounds in drug designing. This paper focuses on screening of lead compounds in arriving at newer drugs for Diabetes mellitus. Aldose reductase a cytosolic enzyme is the receptor to which selected lead compounds are docked. Glycoalkaloids (present in bitter melon) and related compounds were docked onto aldose reductase and based on the GLIDE score, structural modifications were carried out to arrive at the highest GLIDE score. A commercially available molecule recommended for Type 2 Diabetes mellitus was also taken for reference. Glycoalkaloids were found to possess high GLIDE score compared to standard. In order to analyze the competence of the Schrodinger software a comparison was made with an internet freeware Hex 6.3 version. The flexible receptor docking of Schrodinger was found to be more advantageous than the Hex 6.3.","PeriodicalId":164864,"journal":{"name":"Trends in Bioinformatics","volume":"60 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3923/TB.2015.26.36","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Diabetes mellitus is one of the alarming common diseases of this century. In India, according to the statistics of the International Diabetes Federation, 87 million of people are affected by Diabetes mellitus and this number is expected to cross 100 million by 2030. This has created a thrust for the development of new medicines. Recently, ban of pioglitazone, an oral anti-diabetic drug by Drugs Technical Advisory Board (DTAB) on account of its side effects, portrays the need for developing new drugs with less or no side effects. Cheminformatics tools assist in screening several millions of compounds and providing lead compounds in drug designing. This paper focuses on screening of lead compounds in arriving at newer drugs for Diabetes mellitus. Aldose reductase a cytosolic enzyme is the receptor to which selected lead compounds are docked. Glycoalkaloids (present in bitter melon) and related compounds were docked onto aldose reductase and based on the GLIDE score, structural modifications were carried out to arrive at the highest GLIDE score. A commercially available molecule recommended for Type 2 Diabetes mellitus was also taken for reference. Glycoalkaloids were found to possess high GLIDE score compared to standard. In order to analyze the competence of the Schrodinger software a comparison was made with an internet freeware Hex 6.3 version. The flexible receptor docking of Schrodinger was found to be more advantageous than the Hex 6.3.
Maestro 9.4作为一种基于结构筛选醛糖还原酶靶糖生物碱及相关化合物的工具
糖尿病是本世纪令人担忧的常见病之一。根据国际糖尿病联合会的统计,印度有8700万人患有糖尿病,预计到2030年这一数字将超过1亿。这为开发新药创造了动力。最近,药物技术咨询委员会(DTAB)以副作用为由,禁止了口服降糖药吡格列酮,这反映了开发副作用更小或没有副作用的新药的必要性。化学信息学工具有助于筛选数百万种化合物,并为药物设计提供先导化合物。本文重点介绍了糖尿病新药先导化合物的筛选。醛糖还原酶(一种胞质酶)是选定的先导化合物与之对接的受体。糖生物碱(存在于苦瓜中)和相关化合物被对接到醛糖还原酶上,并根据GLIDE评分进行结构修饰,以获得最高的GLIDE评分。一种市售的推荐用于2型糖尿病的分子也作为参考。与标准相比,糖生物碱具有较高的GLIDE评分。为了分析薛定谔软件的能力,与网络免费软件hex6.3版本进行了比较。发现薛定谔柔性受体对接比Hex 6.3更有利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信